Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica
View original at finance.yahoo.comDrug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica AstuteAnalytica India Pvt…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
The drug delivery devices market is entering a super-cycle fueled by an unprecedented convergence of chronic disease prevalence and biologic demand
80% confidenceInvestment magnitude in the drug delivery devices market has reached historic levels as companies race to secure capacity
80% confidenceEli Lilly's total manufacturing pledge reached over US$50 billion between 2020 and early 2025
80% confidenceSHL Medical has set a goal to produce 1.5 billion devices annually by 2025
80% confidenceThe global drug delivery devices market size was valued at US$212.6 billion in 2025 and is projected to reach US$450.7 billion by 2035, growing at a CAGR of 7.8% during the forecast period 2026-2035
80% confidenceThe drug delivery devices market has become the central pillar of pharmaceutical value creation
80% confidenceSuch spending signals a permanent shift from outsourcing toward internalizing critical device production
80% confidenceThe market is surging due to the rising prevalence of chronic diseases and a massive shift toward home-based self-administration
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · novel drug approvals | 61 approvals |
| U.S. Food and Drug Administration · first in class approvals | 24 approvals |
| U.S. Food and Drug Administration · breakthrough therapy approvals | 18 approvals |
| U.S. Food and Drug Administration · biosimilar approvals | 18 approvals |
| U.S. Food and Drug Administration · rare disease approvals | 26 approvals |
| U.S. Food and Drug Administration · priority review approvals | 28 approvals |
| U.S. Food and Drug Administration · fast track approvals | 22 approvals |
| U.S. Food and Drug Administration · first cycle approvals | 37 approvals |